Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on MRNS. Jefferies Financial Group reissued a “hold” rating and issued a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Royal Bank of Canada lowered their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. HC Wainwright restated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Truist Financial downgraded shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Trading Down 0.2 %

NASDAQ MRNS opened at $0.55 on Friday. The stock’s 50-day moving average price is $0.45 and its two-hundred day moving average price is $0.89. The company has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $10.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Marinus Pharmaceuticals during the fourth quarter valued at $54,000. XTX Topco Ltd raised its holdings in shares of Marinus Pharmaceuticals by 1,564.7% in the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 206,614 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Marinus Pharmaceuticals by 266.1% in the fourth quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 354,393 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $36,000. Finally, Deltec Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $107,000. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.